VERTEX PHARMACEUTICALS ($VRTX) is expected to release its quarterly earnings data on Monday, November 3rd after market close, per Finnhub. Analysts are expecting revenue of $3,114,386,471 and earnings of $4.65 per share.
You can see Quiver Quantitative's $VRTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
VERTEX PHARMACEUTICALS Insider Trading Activity
VERTEX PHARMACEUTICALS insiders have traded $VRTX stock on the open market 7 times in the past 6 months. Of those trades, 4 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- RESHMA KEWALRAMANI (CEO & President) has made 2 purchases buying 10,000 shares for an estimated $3,895,767 and 0 sales.
- BRUCE I SACHS has made 2 purchases buying 5,000 shares for an estimated $1,948,415 and 0 sales.
- JONATHAN BILLER (EVP and Chief Legal Officer) sold 694 shares for an estimated $280,521
- SANGEETA N. BHATIA sold 266 shares for an estimated $102,859
- DAVID ALTSHULER (EVP, Chief Scientific Officer) sold 52 shares for an estimated $22,083
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VERTEX PHARMACEUTICALS Hedge Fund Activity
We have seen 662 institutional investors add shares of VERTEX PHARMACEUTICALS stock to their portfolio, and 820 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JENNISON ASSOCIATES LLC removed 2,696,558 shares (-43.8%) from their portfolio in Q3 2025, for an estimated $1,056,079,975
- CAPITAL INTERNATIONAL INVESTORS added 1,986,004 shares (+305.6%) to their portfolio in Q2 2025, for an estimated $884,168,980
- AMUNDI removed 1,965,643 shares (-63.4%) from their portfolio in Q2 2025, for an estimated $875,104,263
- JPMORGAN CHASE & CO removed 1,886,284 shares (-24.3%) from their portfolio in Q2 2025, for an estimated $839,773,636
- VICTORY CAPITAL MANAGEMENT INC added 1,861,279 shares (+633.3%) to their portfolio in Q2 2025, for an estimated $828,641,410
- CAPITAL RESEARCH GLOBAL INVESTORS added 1,571,947 shares (+10.8%) to their portfolio in Q2 2025, for an estimated $699,830,804
- FMR LLC removed 1,320,812 shares (-17.1%) from their portfolio in Q2 2025, for an estimated $588,025,502
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VERTEX PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $VRTX stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR purchased up to $15,000 on 08/07.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 06/11, 06/10.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
VERTEX PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 10/02/2025
- Leerink Partners issued a "Outperform" rating on 09/25/2025
- Evercore ISI Group issued a "Outperform" rating on 09/11/2025
- Guggenheim issued a "Buy" rating on 08/06/2025
- UBS issued a "Buy" rating on 08/05/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/05/2025
- Cantor Fitzgerald issued a "Overweight" rating on 08/05/2025
To track analyst ratings and price targets for VERTEX PHARMACEUTICALS, check out Quiver Quantitative's $VRTX forecast page.
VERTEX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 18 analysts offer price targets for $VRTX in the last 6 months, with a median target of $476.5.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $438.0 on 10/10/2025
- Jessica Fye from JP Morgan set a target price of $530.0 on 10/08/2025
- Geoff Meacham from Citigroup set a target price of $575.0 on 10/02/2025
- David Risinger from Leerink Partners set a target price of $456.0 on 09/25/2025
- Liisa Bayko from Evercore ISI Group set a target price of $475.0 on 09/11/2025
- Mohit Bansal from Wells Fargo set a target price of $460.0 on 08/06/2025
- Whitney Ijem from Canaccord Genuity set a target price of $411.0 on 08/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
